Loading
A phase 2 trial of Nivolumab and Ipilimumab in advanced solid tumours, run by Idera Pharmaceuticals, Inc., active and no longer recruiting.
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) is a phase 2 interventional study registered as NCT03865082 by Idera Pharmaceuticals, Inc., with 30 participants enrolled, started 2019-10-29 and due to reach its primary completion in 2022-03. Interventions recorded: Tilsotolimod, Nivolumab and Ipilimumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ipilimumab, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ipilimumab, Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/